Precigen, Inc. Files Amendment to Annual Report on Form 10-K

TL;DR

<b>Precigen, Inc. has filed an amendment to its 2023 10-K report.</b>

AI Summary

PRECIGEN, INC. (PGEN) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Precigen, Inc. filed an amendment (Amendment No. 1) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The filing was made on April 29, 2024. The company's principal executive offices are located at 20374 Seneca Meadows Parkway, Germantown, Maryland 20876. Precigen, Inc. is incorporated in Virginia. The company's common stock trades under the symbol PGEN on the Nasdaq Global Select Market.

Why It Matters

For investors and stakeholders tracking PRECIGEN, INC., this filing contains several important signals. This amendment indicates potential updates or corrections to the company's previously filed annual financial and operational data. Investors and analysts will review the amended filing for any changes that could impact their assessment of Precigen's financial health and strategic direction.

Risk Assessment

Risk Level: low — PRECIGEN, INC. shows low risk based on this filing. The filing is an amendment to a 10-K, which is a routine update and does not inherently signal significant new risks.

Analyst Insight

Review the specific changes within the 10-K/A filing to understand any updated disclosures or financial adjustments made by Precigen, Inc.

Key Numbers

• 2023-12-31 — Fiscal Year End (Report Period)
• 2024-04-29 — Filing Date (Amendment Submission)
• 001-36042 — Commission File Number (SEC Filing Identifier)
• 26-0084895 — IRS Number (Employer Identification Number)

Key Players & Entities

• PRECIGEN, INC. (company) — Registrant Name
• PGEN (company) — Trading Symbol
• Nasdaq Global Select Market (company) — Exchange
• 20374 Seneca Meadows Parkway (location) — Business Address
• Germantown (location) — City
• Maryland (location) — State
• 20876 (location) — ZIP Code
• Virginia (location) — State of Incorporation

FAQ

Industry Context

Precigen, Inc. operates in the pharmaceutical preparations industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 13 or 15(d), and Regulation S-T for interactive data files.

What Investors Should Do

1. Analyze the specific changes and additions made in Amendment No. 1 to the 10-K filing.
2. Compare the amended information with the original 10-K filing to identify any material differences.
3. Assess the impact of any disclosed changes on Precigen's financial standing and future outlook.

Key Dates

• 2023-12-31: Fiscal Year End — Defines the period covered by the original 10-K filing.
• 2024-04-29: Filing Date of 10-K/A — Indicates when the amendment was submitted to the SEC.

Year-Over-Year Comparison

This filing is an amendment (10-K/A) to the previously filed annual report for the fiscal year ended December 31, 2023.

Key Financial Figures

• $2.3 billion — 's largest law firms with approximately $2.3 billion in revenues with 2,650 law professional

Filing Documents

• tm2412855d1_10ka.htm (10-K/A) — 617KB
• tm2412855d1_ex31-3.htm (EX-31.3) — 4KB
• tm2412855d1_ex31-4.htm (EX-31.4) — 4KB
• 0001104659-24-054003.txt (&nbsp;) — 917KB
• pgen-20231231.xsd (EX-101.SCH) — 3KB
• pgen-20231231_lab.xml (EX-101.LAB) — 36KB
• pgen-20231231_pre.xml (EX-101.PRE) — 24KB
• tm2412855d1_10ka_htm.xml (XML) — 6KB

Signatures

Signatures 38 i PART III Item10. Directors, Executive Officers and Corporate Governance. Information About Our Directors The following table identifies our current directors and sets forth certain information regarding the members of our board of directors, including their ages as of April 29, 2024, and years of tenure on our board of directors (the "Board"). Name Positions and Offices Held with Precigen Director Since Age Randal Kirk Executive Chairman of the Board 2008 70 Cesar Alvarez Director, Chair of Nominating and Governance Committee 2008 76 Steven Frank Director 2008 64 Vinita Gupta Director, Member of Nominating and Governance Committee 2017 56 Fred Hassan Director, Member of Compensation and Human Capital Management Committee 2016 78 Jeffrey Kindler Chair of Audit Committee Member of Compensation and Human Capital Management Committee 2011 68 Dean Mitchell Director, Member of Audit Committee 2009 68 Helen Sabzevari, Ph.D. Director, Chief Executive Officer 2020 62 James Turley Director, Lead Independent Director Chair of Compensation and Human Capital Management Committee 2014 68 The names and certain biographical information about our current directors, including each director's business experience, director position held, information regarding involvement in certain legal or administrative proceeding, if applicable, and the director's experiences, qualifications, attributes, or skills are set forth below. Randal Kirk has served as Executive Chairman of the Board since January 2020 and previously served as Chairman of the Board from February 2008 until December 31, 2019, and as our CEO from April 2009 until December 31, 2019. Mr. Kirk provides a wealth of strategic, operational, and management experience. Mr. Kirk currently serves as Chairman and Senior Managing Director of Third Security, LLC, an investment management firm founded by Mr. Kirk in March 1999. Additionally, Mr. Kirk founded and bec

View Full Filing

View this 10-K/A filing on SEC EDGAR